Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Open-Label Phase II Study to Assess the Efficacy & Safety of AZD4547 Monotherapy Versus Paclitaxel in Patients With Advanced Gastric Adenocarcinoma (Inc. Adenocarcinoma of the Lower Third of the Oesophagus or the Gastro-Oesophageal Junction)With FGFR2 Polysomy or Gene Amplification.

NCT01457846 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01457846
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01457846 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Open-Label Phase II Study to Assess the Efficacy & Safety of AZD4547 Monotherapy Versus Paclitaxel in Patients With Advanced Gastric Adenocarcinoma (Inc. Adenocarcinoma of the Lower Third of the Oesophagus or the Gastro-Oesophageal Junction)With FGFR2 Polysomy or Gene Amplification.
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Terminated
Start date
November 30, 2011
Completion date
February 28, 2015
Enrollment
960 (actual)
Sites
61

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer, gastro-oesophageal junction cancer